START (Strategic Timing of AntiRetroviral Therapy) is an international randomized trial to determine whether starting antiretroviral therapy (ART) early (before the CD4 count drops to less than 500 cells/mm³), rather than waiting until the CD4 count drops to less than 350 cells/mm³ , reduces the occurrence of serious morbidity and mortality.

The EudraCT number for START is: 2008-006439-12.

For additional information about the study or help in using the EudraCT number please contact CHIP.

For further details about the trial go to the INSIGHT website. Latest START Newsletter here

Updated: 18 Dec 2012